Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM

Type1 Diabetes Clinical Trial

Official title:

A Randomized, Double-blind, Two Period, Cross Over Glucose Clamp Study to Test for Bioeqivalence Between Two Long Acting Insulin Analogs-Wockhardt's Glaritus™ (Insulin Glargine) and Lantus (Insulin Glargine) in Subjects With Type 1 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01357603
• Other study ID #: Glaritus/PK-PD/FDA/2011
• Status: Completed
• Phase: Phase 1
• First received: May 12, 2011
• Last updated: January 24, 2013
• Start date: June 2011
• Est. completion date: August 2012

Study information

• Verified date: January 2013
• Source: Wockhardt
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The aim of this trial is to demonstrate bioequivalence of Glaritus® to Lantus® with regard to its total and to its maximum serum insulin concentrations.

Description:

The purpose of this study is to test for bioequivalence based on the pharmacokinetic parameter AUC INS-GLR 0-24h and on pharmacodynamic parameter AUC GIR 0-24h between the two long-acting insulin glargine formulations, Lantus® and Wockhardt's Glaritus® in subjects with type1 diabetes as well as assessing safety and local tolerability of the two insulin preparations.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 111
• Est. completion date: August 2012
• Est. primary completion date: May 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Male or female subjects with type 1 diabetes =12 months.

2. HbA1c =9% by local laboratory analysis (one retest within a week is permitted with the result of the last test being conclusive).

3. Age =18 and =60 years.

4. Considered generally healthy upon completion of medical history, physical examination and biochemical investigations as judged by the Investigator.

5. Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject).

Exclusion Criteria:

1. Previous participation in this trial, or participation in other clinical trials within the last 30 days.

2. Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures (e.g. intrauterine device (IUD) that has been in place for at least 3 months, or sterilization, or the oral contraceptive pill, which should have been taken without difficulty for at least 3 months, an approved hormonal implant or double barrier method including male condoms used plus spermicide, diaphragm with spermicide plus male condom, cap with spermicide plus male condom).

3. History of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose risk in administering the trial drug to the subject. In particular, subjects with significant cardiovascular disease, anemia (hemoglobin below the lower limit of normal) or hemoglobinopathy will not be allowed to enter the trial.

4. Cardiac problems defined as decompensated heart failure (New York Heart Association (NYHA) class III and IV) at any time and/or angina pectoris within the last 12 months and/or acute myocardial infarction at any time.

5. Clinically significant abnormal ECG at screening, as judged by the Investigator.

6. History of alcohol or drug abuse in the past five years.

7. Any positive reaction of drug abuse.

8. Hepatitis B or C or HIV positive.

9. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

10. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.

11. Regular cigarette smoker, defined as smoking >1 pack/day and unable to refrain from smoking during the in house period.

12. Known or suspected allergy to trial product or related products.

13. Any disease or condition that, in the opinion of the Investigator, would represent an unacceptable risk for the subject's safety.

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Type1 Diabetes

Intervention

Biological:
• Glargine
dosage form: Subcutaneous injection

Locations

Country	Name	City	State
United States	Profil Institute for clinical Research	Chula Vista	California

Sponsors (1)

Lead Sponsor	Collaborator
Wockhardt

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bioequivalence based on Pharmacokinetic parameter:AUC INS-GLR 0-24h.		over 24hrs post dose	No
Primary	Bioequivalence based on Pharmacodynamic parameter: AUC GIR 0-24hrs		over 24hrs post dose	No
Primary	Pharmacokinetic Parameters: Maximum concentration (Cmax)		over 24hrs post dose	No
Secondary	Safety parameters	Number of AE's, SAE's, Hypoglycemic events and local tolerability	till 24 hrs post-dose	Yes
Secondary	Pharmacodynamic parameters: Area under curve glucose infusion rate from 0-24hrs	AUC GIR 0-12h,AUC GIR 12-24h,AUC GIR 0-24h	over 24hrs post dose	No
Secondary	Pharmacokinetic parameter: Area under curve from 0-24hrs	AUC INS-GLR 0-12hrs, AUC INS-GLR 12-24hrs,AUC INS-GLR 0-24hrs	over 24hrs post dose	No
Secondary	Pharmacokinetic Parameters: tmax and t1/2		over 24hrs post dose	No
Secondary	Pharmacodynamic parameter: GIR max and tGIR max		over 24hrs post dose	No